United-Guardian (UG) Q3 2024 earnings summary

Executive summary

• Net sales for Q3 2024 were $3.06M, nearly flat year-over-year; nine-month sales rose 17% to $9.71M, driven by strong cosmetic ingredient sales, offset by declines in pharmaceuticals and discontinued industrial products.

• Net income for Q3 2024 was $865K (up 20% year-over-year); nine-month net income rose 49% to $2.75M, reflecting higher sales and improved gross margins.

• Cosmetic ingredient sales surged, especially to ASI, with significant growth in China; Q3 sales up 8% and nine months up 68%, led by major distributors.

• Pharmaceutical sales declined 6% in Q3 and 11% for nine months due to supply disruptions, with recovery anticipated.

• Gross margin improved as cosmetic ingredients, which carry higher margins, made up a larger share of sales.

Financial highlights

• Q3 2024 net sales: $3.06M (flat year-over-year); nine months: $9.71M (up 17%).

• Q3 2024 net income: $865K (up from $627K); nine months: $2.75M (up from $1.84M).

• Q3 2024 EPS: $0.19 (up from $0.14); nine months: $0.60 (up from $0.40).

• Operating income for Q3 increased to $949K from $722K; for nine months, rose to $3.09M from $2.07M.

• Investment income and gains on marketable securities contributed $147K in Q3, up from $65K last year.

Outlook and guidance

• Management expects working capital to be sufficient for at least the next 12 months.

• Anticipates launch of new Natrajel® sexual wellness line in 2025; no sales yet in 2024.

• Ongoing capital projects include facility upgrades, with completion expected by year-end.

• Expectation of continued sales growth as pharmaceutical supply recovers from prior disruptions.